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Linked CsF reduction of 
phosphorylated tau and IL-8 in HIV 
associated neurocognitive disorder
tugba ozturk1,2, Alexander Kollhoff1,2, Albert M. Anderson3, J. Christina Howell1,2, 
David W. Loring1, Drenna Waldrop-Valverde4, Donald Franklin5, Scott Letendre5, 
William R. tyor1,6 & William T. Hu  1,2
HIV-associated neurocognitive disorder (HAND) is a common condition in both developed and 
developing nations, but its cause is largely unknown. Previous research has inconsistently linked 
Alzheimer’s disease (AD), viral burden, and inflammation to the onset of HAND in HIV-infected 
individuals. Here we simultaneously measured cerebrospinal fluid (CSF) levels of established amyloid 
and tau biomarkers for AD, viral copy numbers, and six key cytokines in 41 HIV-infected individuals 
off combination anti-retroviral therapy (14 with HAND) who underwent detailed clinical and 
neuropsychological characterization, and compared their CSF patterns with those from young healthy 
subjects, older healthy subjects with normal cognition, and older people with AD. HAND was associated 
with the lowest CSF levels of phosphorylated tau (p-Tau181) after accounting for age and race. We also 
found very high CSF levels of the pro-inflammatory interferon gamma-induced protein 10 (IP-10/
CXCL10) in HIV regardless of cognition, but elevated CSF interleukin 8 (IL-8/CXCL8) only in HIV-NC but 
not HAND. Eleven HIV-infected subjects underwent repeat CSF collection six months later and showed 
strongly correlated longitudinal changes in p-tau181 and IL-8 levels (R = 0.841). These data suggest 
reduced IL-8 relative to IP-10 and reduced p-Tau181 to characterize HAND.
HIV-associated neurocognitive disorders (HAND) can affect up to 50% of people living with HIV1–3. With more 
than 1.1 million Americans currently living with HIV4, HAND is a more common cognitive disorder than fron-
totemporal dementia5 or Lewy body dementia6. In the era of combination anti-retroviral therapy (cART)7, severe 
HIV-associated dementia is less common in developed nations but milder forms of HAND8–10 can still interfere 
with job performance and compliance with the complex multi-drug combination11. At the same time, accurate 
clinical diagnosis of mild HAND (such as asymptomatic neurocognitive impairment and mild neurocognitive 
disorder)12 remains challenging because of common confounds (e.g., substance abuse). Biofluid or imaging 
markers have the potential of enhancing early and accurate detection of mild HAND. Such biomarkers will be 
especially important in drug development if they also reflect known disease mechanisms or provide new patho-
physiologic insight.
Whereas post-mortem studies commonly associated viral infection as a key mechanism in HIV-associated 
dementia13, no neuropathologic process has been consistently identified in HAND14. Gliosis was the most com-
mon finding15,16, and inclusions associated with age-related neurodegenerative disorders such as Alzheimer’s 
disease (AD) were variably identified. Cerebral PET imaging for neuritic plaques also failed to show increased 
amyloid deposition in HAND17. On the other hand, some ante-mortem cerebrospinal fluid (CSF) studies exam-
ining established AD biomarkers paradoxically showed changes in HAND similar to AD. Two US studies – but 
not one Dutch study – revealed reduced levels of beta-amyloid 1–42 (Aβ42) suggestive of amyloid deposition18–20, 
while levels of total tau (t-Tau) and tau phosphorylated at threonine 181 (p-Tau181) associated with HAND can be 
increased, normal or reduced18,21–23. Because we24,25 and others26 have shown that African American race and CSF 
1Department of neurology, emory University School of Medicine, Atlanta, GA, USA. 2center for neurodegenerative 
Diseases, emory University School of Medicine, Atlanta, GA, USA. 3Department of Medicine – Division of 
infectious Disease, emory University School of Medicine, Atlanta, GA, USA. 4center for neurocognitive Studies, 
emory University Hodgson Woodruff School of nursing, Atlanta, GA, USA. 5HiV neurobehavioral Research 
center, University of california, San Diego, cA, USA. 6Atlanta Veterans Affairs Medical Center, Decatur, GA, USA. 
correspondence and requests for materials should be addressed to A.M.A. (email: aande2@emory.edu) or W.t.H. 
(email: wthu@emory.edu)
Received: 1 February 2019
Accepted: 6 June 2019
Published: xx xx xxxx
OPEN
2Scientific RepoRts |          (2019) 9:8733  | https://doi.org/10.1038/s41598-019-45418-2
www.nature.com/scientificreportswww.nature.com/scientificreports/
proteins also influence measured CSF AD biomarker levels, an investigation into the relationship between these 
biomarkers and HAND must account for race and age by recruiting the appropriate comparison groups. Taking 
advantage of the standardized biofluid collection, handling, and analysis protocols across the HIV and Cognitive 
Clinics at Emory University, we analyzed AD biomarkers in a cohort of 143 subjects, including 41 infected with 
HIV who were off (n = 39) or naïve to cART (n = 2), 33 young healthy subjects with normal cognition (NCyoung), 
44 older healthy subjects with normal cognition (NColder), and 25 older subjects with mild cognitive impairment 
or mild dementia due to AD (MCI/AD). We further explored whether CSF AD biomarker levels in HAND were 
influenced by viral load and altered levels of key CSF cytokines linked to innate immunity or T-cell-related path-
ways (selected for biological function and reproducibility in CSF assays), including interferon-γ-inducible protein 
10 (CXCL10/IP10), interleukin 8 (CXCL8/IL-8), fractalkine (CX3CL1), tumor necrosis factor alpha (TNF-α), 
macrophage-derived chemokine (MDC), and interleukin 10 (IL-10). Finally, to lend support for a mechanistic 
link between AD biomarkers and inflammation, we examined in a group of HIV subjects with serial CSF collec-
tion whether the two biomarker sets underwent parallel changes over time.
Results
HAND was associated decreased CSF p-Tau181 levels. We first compared levels of CSF AD biomark-
ers (Aβ42, t-Tau, p-Tau181) according to cognition (normal vs. impaired; see Methods), HIV status (infected or 
not-infected), and age (Table 1). Consistent with the positive correlation between tau markers and age from a 
large European cohort of healthy middle-aged adults27, NColder had higher t-Tau and p-Tau181 levels than NCyoung. 
Among younger subjects (<60 years of age), HIV with normal cognition (HIV-NC) and HAND were both associ-
ated with lower p-Tau181 and Aβ42 levels than NCyoung (Fig. 1a–c, no significant differences in t-Tau levels). Analysis 
of co-variance (ANCOVA) in the whole cohort (n = 143) showed African American race (F(3, 138) = 14.798, 
p < 0.001)25, having HIV (F = 7.249, p = 0.008), and having HAND (represented by the interaction term between 
cognitive impairment and having HIV, F = 4.764, p = 0.031) were independently associated with reduced p-Tau181 
levels, while older age (F = 7.066, p = 0.009) and cognitive impairment due to AD (F = 2.982, p = 0.086) were 
associated with increased p-Tau181 levels. For Aβ42, lower levels were associated with cognitive impairment 
(F = 21.205, p < 0.001), cognitive impairment due to AD (F = 7.922, p = 0.006), and female gender (F = 8.207, 
p = 0.005). Hence, reduced p-Tau181 was a feature of both HIV (regardless of cognition) and additionally 
HAND, while reduced Aβ42 was associated specifically with AD and non-specifically with cognitive impairment. 
Importantly, there was a strong correlation between Aβ42 and p-Tau181 levels in the younger population, which 
has not been previously reported in older healthy controls from AD studies. A review of prior studies which 
identified HIV/HAND-associated alterations in CSF AD biomarkers also showed four out of five previous studies 
to report changes in Aβ42 and tau along the same direction (three showing paralleled decreases, Table 2, in con-
trast to the opposite directions of change in AD)18,19,28,29. Taken together, we propose that reduced Aβ42 levels in 
HAND are best interpreted as surrogates for reduced p-Tau181.
NCyoung 
(n = 31)
HIV-NC 
(n = 27)
HAND 
(n = 14)
NColder 
(n = 44)
MCI/AD 
(n = 25)
Male (%) 21 (68%) 22 (82%) 11 (79%) 20 (45%) 12 (48%)
African American (%) 13 (42%) 24 (89%)* 12 (86%)* 19 (43%) 12 (48%)
Age (SD), yr 36.9 (11.1) 40.8 (8.7) 38.0 (10.0) 71.1 (6.4)* 72.0 (11.1)*
Education (SD), yr 15.0 (2.4) 13.3 (2.5) 13.0 (2.2) 16.8 (2.4)* 16.7 (2.6)
Age of diagnosis (SD), yr N.A 31.2 (6.5) 27.3 (15.0) N.A N.A
Disease duration (SD), yr N.A 9.4(8.8) 10.2 (9.4) N.A N.A
Time since last cART (SD), mo N.A. 14.9 (13.5) 12.6 (11.1) N.A. N.A.
Log10(plasma viral load) N.D. 4.46 (0.80) 5.12 (0.85) N.D. N.D.
Log10(CSF viral load) N.D. 2.97 (1.05) 3.28 (1.03) N.D. N.D.
CSF AD biomarkers (SD)
   Aβ42, pg/mL 238 (144) 176 (100) 139 (111)* 262 (124) 83 (39)*
   t-Tau, pg/mL 28.6 (13.3) 25.6 (12.0) 22.1 (10.1) 51.4 (25.8)* 71.5 (48.5)*
   p-Tau181, pg/mL 12.7 (4.0) 9.6 (3.9) 8.7 (5.2)* 18.8 (9.5)* 24.4 (14.2)*
CSF cytokines (SD)
   IL-8, pg/mL 66 (17) 113 (49)* 79 (20) 92 (27)* 79 (23)
   IP-10, ng/mL 2.5 (3.1) 11.5 (5.9)* 10.7 (6.3)* 4.2 (2.3) 3.2 (1.4)
   Fractalkine, pg/mL 142 (37) 177 (33)* 171 (26)* 73 (12)* 73 (13)*
   TNF-α, pg/mL 1.8 (0.9) 4.5 (3.3)* 4.7 (4.5)* 2.2 (0.8) 2.1 (0.9)
   MDC, pg/mL 86 (46) 194 (229)* 123 (124)* 175 (78)* 189 (101)*
   IL-10, pg/mL 5.2 (2.7) 8.8 (8.5)* 6.8 (4.6) 7.1 (1.6) 6.8 (1.9)
Table 1. Demographics of subjects included in the study (NCyoung: subjects with normal cognition under the 
age of 60; HIV-NC: HIV-infected subjects with normal cognition; HAND: HIV-infected subjects with cognitive 
impairment; NColder: subjects with normal cognition at or over the age of 60; MCI-AD: subjects with mild 
cognitive impairment and CSF biomarkers consistent with Alzheimer’s disease). *p ≤ 0.003 vs. NCyoung.
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HAND was associated with higher plasma viral load and relative decrease in IL-8. We next ana-
lyzed how HIV infection and neuroinflammation differed according to age, HIV, and cognition. Compared to 
HIV-NC, HAND subjects had been off cART for similar periods of time prior to neuropsychological and CSF 
analysis (14.9 vs 12.6 months, p = 0.625). HAND subjects had higher plasma viral load than HIV-NC subjects 
(log10[plasma viral load] of 5.12 vs. 4.46, p = 0.024, Fig. 2a), and a trend of higher CSF viral load (log10[CSF viral 
load] of 3.17 vs. 2.66, p = 0.167). Entering plasma (F(2, 31) = 0.481, p = 0.494) or CSF (F(2, 31) = 0.001, p = 0.975) 
HIV titer into the above analysis did not change the effect of HAND on p-Tau181.
CSF HIV-NC and HAND were also both associated with higher levels of multiple correlated cytokines than 
NCyoung, including CSF IP-10 (Fig. 2b, F(2, 138) = 105.875, p < 0.001), fractalkine (F = 54.637, p < 0.001), TNF-α 
(F = 33.935, p < 0.001), MDC (F = 7.697, p = 0.006), and IL-10 (F = 5.951, p = 0.016). In contrast, IL-8 levels 
were only elevated in HIV-NC but not HAND (Fig. 2c), with IL-8 levels indistinguishable between NCyoung and 
HAND. ANCOVA accounting for age and CSF HIV load among HIV-infected subjects only showed HAND (F(2, 
37) = 5.038, p = 0.031) associated with decreased IL-8 levels (CSF – but not plasma – HIV load also associated 
with greater IL-8 levels, F(2,37) = 3.461, p = 0.071). Therefore, the selectively attenuated or muted IL-8 changes 
in HIV were a unique cytokine feature for HAND.
Because group-level differences in IP-10 and IL-8 may reflect differential assay performance and other phys-
iologic processes rather than any mechanistic importance related to HAND, we further tested this dissociation 
between IP-10 and IL-8 according to cognitive impairment in HIV at the individual level. This is especially rel-
evant to resolve conflicting findings on absolute cytokine levels from different studies (Table 2)20,30. To do so, we 
first converted each individual’s IL-8 and IP-10 levels into Z-scores (using NCyoung and NColder as the normative) 
Figure 1. CSF AD biomarkers according to cognition and HIV. HIV-NC and HAND subjects had lower CSF 
p-Tau181 levels than NCyoung (a), but not t-Tau levels (b). HAND subjects also had lower CSF Aβ42 levels than 
NCyoung (c). For comparison, MCI/AD subjects had higher p-Tau181 and t-Tau levels, and lower Aβ42 levels than 
NColder. Bars represent median and interquartile range.
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to allow for easier comparison of two cytokines’ effect sizes according to each standard deviation alteration31,32. 
We then examined, within each individual, IL-8 and IP-10 levels relative to each other by difference between the 
two Z-scores (IL-8 and IP-10)33. In other word, an individual with proportional increase in IL-8 and IP-10 would 
have a Z-score difference of 0, while another individual with disproportional increase in IP-10 would have a neg-
ative Z-score difference (bias towards IP-10). Through this analysis, we found that HAND was associated with 
the greatest unopposed change in IP-10 relative to IL-8, while the other groups had relatively balanced changes 
in IL-8 and IP-10 (Fig. 2d).
Longitudinal p-tau181 and IL-8 level alterations were highly correlated. As HAND was charac-
terized by both reduced p-Tau181 levels and a relative reduction in IL-8 (compared to HIV-NC), we next tested 
whether these two markers undergo paralleled changes over time. Follow-up CSF samples were obtained from 
eleven subjects (27% of original cohort, including 8 HIV-NC and 3 HAND) six months after the baseline collec-
tion. When change in biomarker levels were log2-transformed to give equal weight to increases and decreases, 
we found longitudinal changes in p-Tau181 levels to strongly correlate with changes in IL-8 (R = 0.841, p = 0.001, 
Fig. 3a) and, to a lesser degree, with IP-10 (Fig. 3b), plasma/CSF viral load, or Aβ42. In contrast, longitudinal 
changes in Aβ42 levels did not correlate with changes in IL-8 (Fig. 3c) or IP-10 (Fig. 3d). Regression analysis 
showed changes in IL-8, rather than IP-10, best predicted changes in p-Tau181. Interestingly, one HIV-infected 
subject classified as HAND at baseline experienced normalization of his cognitive status during follow-up, and 
this was accompanied by increases in both his CSF p-Tau181 and IL-8 levels (Fig. 3a).
Reference Assay Analytes
NC  
(pg/mL)
HIV-NC 
(pg/mL)
HAND/HAD 
(pg/mL) Key Findings
Ellis, 199867 (US) ELISA (Innotest) t-Tau 223 ± 106 185 ± 83 No difference between groups
Brew, 200522 (unknown) ELISA (Innotest)
Aβ42 544 384 153 Lower Aβ42 in HAD than NC (p < 0.0001) 
or HIV-NC (p = 0.038);
Greater p-Tau181 in HAD than NC, p = 0.01
t-Tau 203 288 314
p-Tau181 61 74 89
Clifford, 200918 (US, multi-racial) ELISA (Innotest)
Aβ42 722 683 522 Lower Aβ42 in HAND than HIV-NC 
(p = 0.0027); lower t-Tau and p-Tau181 in 
HAND than NC (p = 0.020, 0.044); lower 
p-Tau181 in HIV-NC than NC (p = 0.0026)
t-Tau 242 183 196
p-Tau181 47 33 40
Ances, 201217 (US, multi-racial) ELISA (Innotest) Aβ42 699 ± 53 615 ± 69 730 ± 116 Greater Aβ42 in HAND than HIV-NC & Control, p = 0.03
Peluso, 201328 (US, Sweden, Australia) ELISA (In house)
Aβ42 650 900 Greater Aβ42 (p = 0.0005) and p-Tau181 
(p = 0.016) in HIV than NC; greater 
p-Tau181 in HIV than NC, p = 0.016
t-Tau 175 200
p-Tau181 29 35
Krut, 201329 (Sweden) ELISA (custom)
Aβ42 700 N/D 486 Lower Aβ42 in HAD than NC, p < 0.05
Lower p-Tau181 in HAD than NC,
p < 0.001
t-Tau 240 N/D 404
p-Tau181 35 N/D 27
Mothapo†, 201520 (Netherlands) ELISA (Millipore) Aβ42 1050 1175 1150 No difference between groups
Cysique, 201568 (Australia) ELISA (Innotest)
Aβ42 N/A N/A N/A
No difference between groupst-Tau N/A N/A N/A
p-Tau181 N/A N/A N/A
Krebs, 201630 (Thailand) ELISA (Life Tech.) t-Tau — N/A N/A No difference between HIV-NC and HAND
de Almeida, 201819 (Brazil) ECL (MSD)
Aβ42 618 448
Lower Aβ42 (p = 0.002) & t-Tau 
(p < 0.001), in HIV than NCt-Tau 634 198
p-Tau181 132 164
Kamat*, 201269 (US multi-racial)
Luminex (BioRad) IL-8 3 47.7 Greater in HIV than NC, p < 0.001
IP-10 5 12.5 Greater in HIV than NC, p = 0.001
Mothapo†, 201520 (Netherlands) Luminex (Millipore) IL-8 25 20 40 Greater IL-8 in HAND than HIV-NC
Yuanǂ, 201538 (China) Luminex (Millipore)
IL-8 — 22.44 100.6 Greater IL-8 in HAND than HIV-NCp = 0.02
IP-10 — 5834 17260 Greater IP-10 in HAND than HIV-NCp = 0.01
Krebs, 201630 (Thailand) Multiplex ELISA (custom) IL-8 N/A N/A N/A No difference between groups
Mehta§, 201737 (US multi-racial) Luminex (Millipore) IP-10 — N/A N/A Greater in top than bottom tertile mtDNA (associated with HAND), p < 0.001
Table 2. Previous studies involving CSF AD biomarker or cytokine alterations in HIV-NC, HAND, or HIV-
associated dementia (HAD). When studies did not distinguish between HIV-NC and HAND, mean values of 
HIV subjects are shown. *55/67 on cART; †5/7 HIV-NC and 14/15 HAND subjects on cART; ǂ17/33 HIV-NC 
and 20/52 HAND subjects on cART; §158/234 of HIV-NC and 72/98 of HAND subjects on cART. ECL: 
electrochemiluminescence; ELISA: enzyme-linked immunosorbent assay.
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Discussion
Here we analyzed CSF AD biomarkers and cytokines in a group of HIV-infected and HIV-negative subjects to 
simultaneously examine two pathways previously implicated in HAND. We identified HAND to be characterized 
by reduced (but correlated) levels of two AD biomarkers (p-Tau181, Aβ42), as well as increased IP-10 levels with-
out accompanying increase in IL-8. These cross-sectional differences may point to a mechanistic link between 
AD biomarkers and inflammation – at least in HIV, because we also found highly correlated changes in IL-8 and 
p-Tau181 levels over time. Because CSF Aβ42 levels correlated directly with p-Tau181 levels in younger subjects 
regardless of HIV status (rather than inverse pattern in AD), we add to the growing literature that CSF biomarkers 
do not suggest a link between HAND and AD.
CSF IL-834–36 and IP-1036,37 have been independently linked to HIV in the past. To the best of our knowledge, 
this is the first report of a dissociation between IP-10 and IL-8 changes in HAND. While prior studies consist-
ently showed elevated CSF IP-10 in HIV-NC and HAND20,37,38, findings in CSF IL-8 were less consistent with 
HAND associated with elevated IL-8 in patients from Netherlands20 and China38 but normal levels in patients 
from the US37. Causes for increased IP-10 and IL-8 levels in HIV are likely complex. There can be migration of 
peripheral immune cells into the central nervous system (CNS), although the magnitude of change from this is 
likely limited39. Non-HIV infected astrocytes release IL-8 in vitro in response to HIV-infected monocyte-derived 
macrophages40, tat protein41, and gp12042. IL-8 increase in HIV may then reflect the number of non-infected 
astrocytes capable of responding to the virus. On the other hand, astrocytes genetically engineered to express 
HIV-1 Nef in vitro show markedly elevated IP-10 mRNA and protein levels, in keeping with the post-mortem 
finding of elevated astrocytic IP-10 in HIV-infected brains43. Therefore, the balance between CSF IL-8 and IP-10 
levels potentially reflects the health of astrocytes in HIV-infected subjects. Because our study of HIV-infected 
patients off cART differs in design from prior studies involving mostly of patients on active cART, diminished 
CSF IL-8 levels in HAND may be reversible with treatment even though this was not universally observed in our 
small cohort of longitudinally characterized patients. Alternatively, discrepant CSF IL-8 findings in HAND may 
Figure 2. Infectious and inflammatory changes in HIV-NC and HAND. Compared to HIV-NC, HAND was 
associated with higher plasma viral load and larger proportion of subjects with detectable CSF viral load (a). 
HIV-NC and HAND were both associated with elevated CSF IP-10/CXCL10 (b) levels, but CSF IL-8 was only 
elevated in HIV-NC (c). When IP-10 and IL-8 levels were normalized against NC subjects, the difference between 
IL-8 and IP-10 Z-scores was the most negative in HAND (d) while NCyoung, NColder, and MCI/AD showed a 
balance (Z-score difference of 0) between IL-8 and IP-10 (bars represent median and interquartile range).
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result from dual infection (more common HAND)44 or race-associated differences in IL8 polymorphism45,46. A 
larger longitudinal CSF study or a quantitative post-mortem analysis of HIV-infected vs. non-infected astrocytes 
will be necessary to fully test this hypothesis.
CSF AD proteins and cytokines have each been analyzed in HIV and HAND in previous studies (Table 2), 
but often separately and rarely with longitudinal CSF collection and analysis. Observations linking HAND to AD 
include in vitro evidence of HIV Tat protein47 or peptide48 inhibiting the primary Aβ42-degrading enzyme nepri-
lysin, and HIV Gag protein mediating the release of Aβ fragments from the amyloid precursor protein49. We have 
ourselves found in vitro evidence of mixed neprilysin inhibition by HIV Tat according to enzyme concentration, 
and acknowledge the potential in vitro overlap between HIV proteins and cellular processes capable of clearing 
and generating AD-related Aβ peptides (unpublished data). However, most studies now (including ours)18,19,29 
have shown decreases in Aβ42 and tau markers, a pattern quite distinct from the AD profile of decreased Aβ42 
but increased tau markers. Human studies therefore strongly favor reduced Aβ42 in HAND as a result of younger 
age instead of AD. While we do not rule out the possibility of cerebral amyloid deposition through non-AD 
related mechanisms in HAND17, the positive identification of reduced p-Tau181 levels and decreased IL-8 (relative 
to IP-10) in HAND warrant further studies on how paired immune dysregulation and tau phosphorylation may 
contribute to neuronal dysfunction in HIV.
It is not known how higher viral load or reduced IL-8 relative to IP-10 are mechanistically linked to reduced 
CSF p-Tau181 levels. We and others have found aging to be associated with increasing CSF p-Tau181 levels, and it 
is not readily apparent why HAND would be associated with greater youthfulness in the brain. Tau hyperphos-
phorylation was previously observed in brains of a transgenic rat model of HIV50, and a post-mortem study 
found the greatest brain tau pathology in patients treated with cART. Our observed association between cognitive 
impairment and low p-Tau181 levels in HIV-infected patients off cART is then in keeping with inadequate viral 
suppression. It is important to note that while elevated t-Tau and p-Tau181 levels have been proposed as markers 
of general neurodegeneration and tau hyperphosphorylation in AD51, such relationships are not seen in other 
common degenerative disorder with rare exception. In fact, we and others have found reduced CSF p-Tau181 
levels in frontotemporal lobar degeneration with lesions immunoreactive to TDP-4352,53, and, to a lesser degree, 
in Parkinson’s disease54. CSF levels of t-Tau and p-Tau181 should then not be used as surrogate markers of neu-
rodegeneration in HIV, but HIV does represent a non-AD process that dynamically alters CSF p-Tau181 levels at 
a rate much faster than observed in other conditions. An improved understanding of if and how HIV infection, 
Figure 3. Longitudinal changes in p-Tau181 and IL-8 were highly correlated to each other (a) in HIV-NC (open 
diamonds) and HAND (filled diamonds), and to a lesser degree between p-Tau181 and IP-10 (b, primarily due 
to association between IP-10 and IL-8). Longitudinal changes in Aβ42 were not correlated to IL-8 (c) or IP-10 
(d). Fold-changes of these markers (∆marker) from baseline CSF sample to follow-up CSF sample were log2-
tranformed to provide equal weight to increases and decreases. One subject (gray diamond) with HAND at 
baseline converted to HIV-NC during follow-up.
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astrocytic health, and cART modify CSF p-Tau181 levels will likely enhance the interpretation of this marker 
beyond just HIV or HAND.
Among candidate mechanisms capable of modifying tau in HIV, HIV-1 Tat enhances CDK5 transloca-
tion55 which leads to increased tau phosphorylation, while calcineurin – an abundant brain phosphatase – can 
dephosphorylate tau. Calcineurin is upregulated in vitro by neurons exposed to HIV gp12056, and is involved 
in reactivating latent HIV57. Calcineurin inhibition in mice genetically engineered to express gp120 also lead 
to reduced neuroinflammation and neuropathology58. Because of the floor effect in CSF HIV viral load meas-
urements, p-Tau181 levels may provide greater sensitivity in monitoring the brain impact of HIV infection espe-
cially given the new automated platforms for AD biomarkers59. Future studies should incorporate measures of 
calcineurin-related peptides, markers of neurodegeneration (e.g., neurofilament light chain, neurogranin) as well 
as p-Tau181 and cytokines to better validate this biomarker combination in HIV and HAND.
In sum, we report that HAND is characterized by lower CSF p-Tau181 levels, a relative decrease in IL-8 com-
pared to IP-10, and a modest increase in plasma viral load. The strong correlation in the first two markers’ longi-
tudinal changes suggest a shared mechanism independent from plasma viral load, and the identification of fluid 
biomarkers may help clarify the transition between HIV-NC and HAND. These markers can potentially be used 
in conjunction with routine viral measures to track insidious cognitive decline, and CSF p-Tau181 levels should be 
tested as a surrogate biomarker of response in clinical trials targeting inflammation in HAND.
Methods
Standard protocol approvals, registrations, and patient consents. The studies were approved by 
the Emory University Institutional Review Board and written informed consent was obtained from all subjects. 
All experiments were performed in accordance with the US Common Rule (45 CFR Part 46), the Declaration of 
Helsinki, and Emory University policies.
Subjects and diagnostic formulation. HIV-infected adult subjects without subacute cognitive decline 
over the prior 30 days AND were off cART (due to compliance, side effects, or insurance related issues) were 
recruited at the Emory University Center for AIDS Research (CFAR) as previously described60. Briefly, each 
subject underwent standard medical evaluation and blood tests (TSH, vitamin B12, serum cryptococcal anti-
gen) to rule out reversible causes of cognitive impairment, followed by standardized neuropsychological testing 
according to the most recent HAND criteria12. For this study, participants were excluded if there was a (1) history 
of neurologic disease known to affect memory (including stroke, malignancy involving the central nervous sys-
tem, traumatic brain injury, and AIDS-related opportunistic infection in the brain), (2) ongoing substance use 
including heavy alcohol consumption in the past 30 days (>7 drinks per week for women and >14 drinks per 
week for men), (3) serious mental illness (e.g, schizophrenia and bipolar disorder; depression was not an exclu-
sion criterion), or 4) history of treated syphilis and a persistently positive rapid plasma regain titer of 1:4 or less. 
HIV-infected subjects were further invited to return for a 6-month follow-up visit, and 11 individuals returned 
for the follow-up visit and underwent a second CSF collection.
All HIV-infected participants underwent comprehensive neuropsychological analysis for the assessment of 
HAND using 14 tests commonly used in studies of cognition and HIV61: (1) Trailmaking Part A, (2) Trailmaking 
Part B, (3) Hopkins Verbal Learning Test total learning, (4) Hopkins Verbal Learning Test delayed recall, (5) 
Brief Visuospatial Memory Test-Revised learning, (6) Brief Visuospatial Memory Test-Revise delayed recall, (7) 
Grooved Pegboard (dominant), (8) Grooved Pegboard (non-dominant), (9) Finger Tapping; (10) Stroop Color 
Naming, (11) Stroop Color-Word interference, (12) Symbol Digit Modalities Test, (13) Letter Fluency (Controlled 
Oral Word Association Test), and (14) Category fluency (animals). These tests were selected in order to examine 
at least five domains as recommended. Age, sex-, race-, and education- adjusted T-scores across 14 subtests were 
averaged to generate a composite neuropsychological score (NPT-14), and the validated global deficit score (GDS) 
was also calculated with a score ≥ 0.5 to indicate cognitive impairment62. A modified standard regression-based 
correction was used to account for longitudinal practice effect when determining changes in neuropsychological 
performance in follow-up63.
NCyoung were also recruited at CFAR (n = 13) or as part of a broader biobanking protocol (n = 18) at Emory 
University. For comparative purposes, we additionally analyzed samples from older African Americans and 
Caucasians with normal cognition (NColder) or MCI/AD (CSF t-Tau/Aβ42 ≥ 0.39 based on a biomarker-autopsy 
cohort)64 recruited under a separate study25. All these subjects underwent standardized clinical examination, 
neuropsychological analysis, consensus diagnosis process, and MR imaging as previously described25,65.
Procedures. In all subjects, plasma and CSF samples were obtained on the same day as neuropsychological 
analysis60. Plasma samples were centrifuged, aliquoted, labeled, and stored at −80 °C until analysis. CSF was 
collected using a modified Alzheimer’s Disease Neuroimaging Initiative protocol with minor modifications. At 
CFAR (all HIV subjects and 17 NCyoung), CSF was obtained without overnight fasting using a 20-Gauge cut-
ting edge needle directly into a 15 mL polypropylene tube, centrifuged to remove cellular debris (1800 RPM for 
10 min), aliquoted, labeled, and immediately frozen. For other subjects, CSF was collected without overnight fast-
ing using a 24-Gauge atraumatic needle directly into a 15 mL polypropylene tube, aliquoted, labeled, and frozen. 
We previously showed that CSF centrifugation to remove cellular debris did not influence measured cytokine 
levels, and samples collected with and without centrifugation can be analyzed together32,66.
Plasma and CSF viral load. Plasma and CSF HIV RNA levels were measured in the real-time HIV-1 
RT-PCR assay (Abbott Molecular, Chicago, IL), with the lowest limit of HIV detection at 40 copies/mL. Plasma 
and CSF viral load were log10-transformed because of their non-normality.
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CSF biomarkers. CSF AD biomarker (Aβ42, t-Tau, p-Tau181) levels were measured in a Luminex 200 plat-
form using Alzbio3 (Fujirebio USA, Malvern, PA) as previously described25,52. Our center achieves an average 
inter-plate coefficient of variation (CV) of 13% for Aβ42, 10% for t-Tau, and 11% for p-Tau181. Levels of six CSF 
cytokines (IP10, IL-8, fractalkine, TNF-α, MDC, IL-10) were measured using Milliplex MAP Human Cytokine/
Chemokine Magnetic Bead Panel (Millipore Sigma, Burlington, MA) in a Luminex 200 platform following the 
manufacturer’s protocol except two 100 μL aliquots of CSF were used for duplicates. These cytokines were previ-
ously selected from a larger panel because of assay sensitivity and intermediate precision in CSF cytokine anal-
ysis. In our laboratory, we achieve average intermediate precision (in experiments performed over 9 days) of 
9.4% for TNF-α, 12.9% for MDC, 14.7% for IL-7, 4.8% for IP-10, 12.0% for IL-10, 9.2% for IL-9, and 7.6% for 
IL-8. Freeze-thawing experiment using CSF from six separate subjects showed significant degradation over two 
freeze-thaw cycles for MDC and TNF-α (p = 0.021 and p = 0.012 for slope in exponential decay), and we previ-
ously showed light centrifugation to have minimal impact on these CSF cytokine levels.
Statistical analysis. All statistical analysis was performed using IBM SPSS 24 (Chicago, IL). ANCOVA was 
used to determine main effects of HIV, cognition, and the interaction term between HIV and cognition on CSF 
biomarker levels, including p-Tau181, t-Tau, Aβ42, IP-10, IL-8, fractalkine, TNF-α, and IL-10. Student’s T-tests 
were used to analyze differences in log10-transformed plasma and CSF viral load between HIV-NC and HAND, 
and Chi-squared test was used to analyze proportion of HIV-NC and HAND subjects with undetectable levels of 
CSF viral load.
To calculate Z-scores for IL-8 and IP-10, mean and standard deviation values from a combined cohort of 
NCyoung and NColder were calculated for each cytokine, and every individual’s IL-8 and IP-10 levels were trans-
formed into Z-scores32. Z-score differences between IL-8 and IP-10 were calculated by subtracting the former’s 
Z-score by the latter’s Z-score33.
Finally, for HIV-infected patients who underwent serial CSF collections, each individual’s biomarker levels 
from the follow-up visits were divided by his or her baseline CSF levels to determine fold-change in IL-8, IP10, 
p-Tau181, and Aβ42 levels. The fold-change values then underwent log2-transformation to give equal weight to 
increases and decreases. Because viral load was already analyzed after log10 transformation, the change in plasma 
viral load was represented by the difference in serial log-transformed values. Pearson’s correlation analysis was 
used to determine relationship between longitudinal changes in these biomarkers.
Data Availability
The de-identified datasets generated and analyzed during the current study are available from the co-correspond-
ing authors on reasonable request.
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